An assessment of the cost-utility of therapy for psoriasis.
Weiss, Stefan C, Wingfield Rehmus, and Alexa B Kimball. 2006. “An Assessment of the Cost-Utility of Therapy for Psoriasis.”. Therapeutics and Clinical Risk Management 2 (3): 325-8.
Search
Search results
410 results found
Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
Feldman, Steven R, Alexa Boer Kimball, Gerald G Krueger, Michael Woolley, Deepa Lalla, and Angelika Jahreis. 2005. “Etanercept Improves the Health-Related Quality of Life of Patients With Psoriasis: Results of a Phase III Randomized Clinical Trial.”. Journal of the American Academy of Dermatology 53 (5): 887-9.
Clobetasol propionate foam in the treatment of psoriasis.
Reid, David C, and Alexa B Kimball. 2005. “Clobetasol Propionate Foam in the Treatment of Psoriasis.”. Expert Opinion on Pharmacotherapy 6 (10): 1735-40.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball, A B, K B Gordon, S Fakharzadeh, N Yeilding, P O Szapary, B Schenkel, C Guzzo, S Li, and K A Papp. 2012. “Long-Term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis: Results from the PHOENIX 1 Trial through up to 3 Years.”. The British Journal of Dermatology 166 (4): 861-72.
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Langley, Richard G, Steven R Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B Gordon, and Alexa B Kimball. 2010. “Ustekinumab Significantly Improves Symptoms of Anxiety, Depression, and Skin-Related Quality of Life in Patients With Moderate-to-Severe Psoriasis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Trial.”. Journal of the American Academy of Dermatology 63 (3): 457-65.
Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study.
Donigan, Jessica M, Vanessa L Pascoe, and Alexa B Kimball. 2015. “Psoriasis and Herpes Simplex Virus Are Highly Stigmatizing Compared With Other Common Dermatologic Conditions: A Survey-Based Study.”. Journal of the American Academy of Dermatology 73 (3): 525-6.
Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term Outcomes of Individuals with Psoriasis.
Kim, Grace E, Elizabeth Seidler, and Alexa Boer Kimball. 2015. “Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term Outcomes of Individuals With Psoriasis.”. Pediatric Dermatology 32 (5): 656-62.
Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.
Zhu, B, E Edson-Heredia, J Guo, T Maeda-Chubachi, W Shen, and A B Kimball. 2014. “Itching Is a Significant Problem and a Mediator Between Disease Severity and Quality of Life for Patients With Psoriasis: Results from a Randomized Controlled Trial.”. The British Journal of Dermatology 171 (5): 1215-9.
The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients.
Kim, G E, E Seidler, and A B Kimball. 2014. “The Relative Impact of Psoriasis and Obesity on Socioeconomic and Medical Outcomes in Psoriasis Patients.”. Journal of the European Academy of Dermatology and Venereology : JEADV 28 (2): 216-21.
Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence.
Kimball, A B. 2012. “Psoriasis and Cardiovascular Disease: Another Contribution in the Hierarchy of Evidence.”. The British Journal of Dermatology 167 (6): 1198-9.